AtriCure, Inc. (ATRC) Insider Trading Activity

NASDAQ$27.1
Market Cap
$1.37B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
455 of 870
Rank in Industry
28 of 43

ATRC Insider Trading Activity

ATRC Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$1,707,760
12
100

Related Transactions

Prange Karendirector
0
$0
1
$85,950
$-85,950
GROVES REGINA Edirector
0
$0
1
$90,283
$-90,283
Yuen Maggiedirector
0
$0
1
$107,160
$-107,160
Noznesky Justin JChief Mktg & Strategy Officer
0
$0
2
$301,540
$-301,540
Doraiswamy VinayakChief Scientific Officer
0
$0
3
$381,250
$-381,250
WEHRWEIN SVENdirector
0
$0
4
$741,578
$-741,578

About AtriCure, Inc.

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Insider Activity of AtriCure, Inc.

Over the last 12 months, insiders at AtriCure, Inc. have bought $0 and sold $1.71M worth of AtriCure, Inc. stock.

On average, over the past 5 years, insiders at AtriCure, Inc. have bought $111,250 and sold $2.59M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $111,250 was made by Privitera Salvatore (Chief Technical Officer) on 2024‑05‑30.

List of Insider Buy and Sell Transactions, AtriCure, Inc.

2026-05-20SalePrange Karendirector
3,000
0.0059%
$28.65
$85,950
-1.58%
2026-05-15SaleDoraiswamy VinayakChief Scientific Officer
5,000
0.0099%
$28.13
$140,650
-1.39%
2026-03-12SaleDoraiswamy VinayakChief Scientific Officer
5,000
0.0101%
$29.83
$149,150
-3.29%
2025-11-26SaleNoznesky Justin JChief Mktg & Strategy Officer
5,166
0.0108%
$37.29
$192,640
-14.83%
2025-11-25SaleWEHRWEIN SVENdirector
4,967
0.0105%
$38.00
$188,746
-19.62%
2025-11-24SaleWEHRWEIN SVENdirector
5,033
0.0104%
$37.32
$187,832
-17.96%
2025-11-21SaleYuen Maggiedirector
3,000
0.006%
$35.72
$107,160
-14.32%
2025-09-12SaleNoznesky Justin JChief Mktg & Strategy Officer
3,000
0.0062%
$36.30
$108,900
-5.19%
2025-08-22SaleWEHRWEIN SVENdirector
5,000
0.0099%
$37.00
$185,000
-8.26%
2025-08-19SaleWEHRWEIN SVENdirector
5,000
0.0101%
$36.00
$180,000
-3.24%
2025-08-06SaleGROVES REGINA Edirector
2,452
0.0048%
$36.82
$90,283
-4.13%
2025-08-05SaleDoraiswamy VinayakChief Scientific Officer
2,500
0.0049%
$36.58
$91,450
-6.71%
2025-05-28SaleDoraiswamy VinayakChief Scientific Officer
2,500
0.005%
$33.44
$83,600
+1.91%
2025-03-05SalePrange Karendirector
6,100
0.0124%
$38.12
$232,532
-8.67%
2024-08-15SaleYuen Maggiedirector
3,500
0.0082%
$24.07
$84,245
+36.80%
2024-05-30PurchasePrivitera SalvatoreChief Technical Officer
5,000
0.0103%
$22.25
$111,250
+40.88%
2024-05-01SaleNoznesky Justin JChief Mktg & Strategy Officer
1,500
0.003%
$24.09
$36,135
+19.00%
2024-04-01SaleNoznesky Justin JChief Mktg & Strategy Officer
1,500
0.0033%
$30.39
$45,585
-3.99%
2024-03-18SaleDahlquist Karl S.Chief Legal Officer
1,885
0.004%
$32.16
$60,622
-12.70%
2024-03-12SaleNoznesky Justin JChief Mktg & Strategy Officer
1,500
0.0033%
$36.72
$55,080
-20.21%
Total: 361
*Gray background shows transactions not older than one year

Insider Historical Profitability

24.91%
Doraiswamy VinayakChief Scientific Officer
91875
0.1814%
$2.49M05
Noznesky Justin JChief Mktg & Strategy Officer
78798
0.1556%
$2.14M017
WEHRWEIN SVENdirector
34374
0.0679%
$931,535.4005
GROVES REGINA Edirector
33715
0.0666%
$913,676.5034
+38.8%
Prange Karendirector
26373
0.0521%
$714,708.3003
Yuen Maggiedirector
11371
0.0225%
$308,154.1003
Discovery Group I, LLC10 percent owner
1621334
3.2016%
$43.94M4725
+15.37%
CARREL MICHAEL HPresident, CEO, & Director
504795
0.9968%
$13.68M025
ROBARDS KAREN Pdirector
288328
0.5694%
$7.81M233
+76.77%
Wrubel Lee Rdirector
285717
0.5642%
$7.74M021
HARRISON DONALD Cdirector
198741
0.3925%
$5.39M02
Drachman David JPresident and CEO
146000
0.2883%
$3.96M415
<0.0001%
Wade M. AndrewCFO
145120
0.2866%
$3.93M09
Privitera SalvatoreChief Technical Officer
103290
0.204%
$2.8M111
+40.88%
Piton Julie AVP Fin & Admin & CFO
85922
0.1697%
$2.33M12
<0.0001%
Collar Mark Adirector
77307
0.1527%
$2.1M210
<0.0001%
Wirick Angela LChief Financial Officer
70146
0.1385%
$1.9M02
LUX ANDREW LSVP, Ops & Quality
65589
0.1295%
$1.78M12
+17.91%
Seith Douglas JChief Operating Officer
64711
0.1278%
$1.75M215
+43.56%
Hooven Michael Ddirector
57049
0.1127%
$1.55M78
<0.0001%
Lucky James LVP, Clinical, Regulatory & QS
51250
0.1012%
$1.39M011
Dahlquist Karl S.Chief Legal Officer
50954
0.1006%
$1.38M07
Drake Scott Williamdirector
41036
0.081%
$1.11M22
+73.02%
JOHNSTON RICHARD Mdirector
34727
0.0686%
$941,101.70121
+13.46%
Lanning Mark Rdirector
25000
0.0494%
$677,500.0030
+43.44%
Preiss FrederickVice President Operations
24000
0.0474%
$650,400.0004
Krell Elizabeth Ddirector
19967
0.0394%
$541,105.70112
<0.0001%
Austin TonyaChief Human Resources Officer
17621
0.0348%
$477,529.10013
JOHNSON B KRISTINEdirector
10969
0.0217%
$297,259.9010
+27.76%
PRESIDIO MANAGEMENT GROUP VIII L L C10 percent owner
9858
0.0195%
$267,151.8003
Walsh Richard SVice President; Sales
1750
0.0035%
$47,425.0020
<0.0001%
*Gray background shows insiders who have made transactions during last year

ATRC Institutional Investors: Active Positions

Increased Positions134+60.09%7M+13.95%
Decreased Positions95-42.6%5M-11.43%
New Positions40New4MNew
Sold Out Positions24Sold Out3MSold Out
Total Postitions262+17.49%49M+2.52%

ATRC Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$190,102.009.68%4.84M-65,324-1.33%2025-09-30
Wellington Management Group Llp$168,550.008.58%4.29M+322,818+8.13%2025-09-30
Blackrock, Inc.$156,966.007.99%4M-25,359-0.63%2025-09-30
Alliancebernstein L.P.$139,746.007.12%3.56M-15,057-0.42%2025-09-30
Hood River Capital Management Llc$119,600.006.09%3.05M-15,472-0.51%2025-09-30
Macquarie Group Ltd$89,904.004.58%2.29M-213,836-8.54%2025-09-30
Champlain Investment Partners, Llc$77,684.003.96%1.98M-38,541-1.91%2025-09-30
State Street Corp$49,649.002.53%1.26M-9,443-0.74%2025-09-30
Neuberger Berman Group Llc$46,775.002.38%1.19M+1,372+0.12%2025-09-30
Geode Capital Management, Llc$46,773.002.38%1.19M+9,318+0.79%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.